2016
Change of Director’s Interest Notice
29/12/2016Change in Substantial Holding
28/12/2016Proteomics Completes Heavily Oversubscribed Share Purchase Plan
28/12/2016Change in Substantial Holding
28/12/2016Change in Substantial Holding
28/12/2016Appendix 3B
19/12/2016Diabetic Kidney Disease Patent Granted in Russia
13/12/2016Appendix 3B
13/12/2016Secondary Trading Notice
07/12/2016Share Purchase Plan Offer Document
06/12/2016Notice Pursuant to ASIC Class Order 09/425
02/12/2016Proteomics Completes $1.44 million Placement and Offers SPP
30/11/2016Trading Halt
17/11/2016Outcome of AGM
17/11/2016Proteomics AGM Presentation
15/11/2016Proteomics and Linear to offer end-to-end testing and clinical trials
11/11/2016PromarkerD Test Kit Production Deal Signed
31/10/2016Proteomics Wins WA Exporter of the Year
26/10/2016Proteomics Presents at Australia Biotech Invest 2016
25/10/2016Quarterly Report – Appendix 4C
20/10/2016Proteomics Targets Gastro-causing Parasite
19/10/2016Notice of Annual General Meeting/Proxy Form
14/10/2016Proteomics Appoints New Director
04/10/2016Research Report
21/09/2016Proteomics International Receives FY16 R&D Tax Incentive
06/09/2016Proteomics Investigates Biomarkers for Mesothelioma
26/08/2016Corporate Governance Statement and Appendix 4G
26/08/2016Annual Report to Shareholders
26/08/2016Appendix 4E – Preliminary Final Report
24/08/2016Proteomics International Expands Diagnostics Portfolio to Endometriosis
28/07/2016Quarterly Business Update
29/06/2016PIQ Board Changes
14/06/2016PromarkerD Development Advances in China
20/05/2016Proteomics Gaining Strong Traction in Analytical Services
15/04/2016Proteomics to Expand Operations in Indian Market
23/03/2016Proteomics Commences Therapeutic Drug Discovery Program
07/03/2016PromarkerD Update
16/02/2016Appendix 3B
09/02/2016New Company Website and Corporate Video
21/01/2016Proteomics International Quarterly Business Update
